According to a recent LinkedIn post from Antag Therapeutics, the company’s executives are scheduled to deliver both an oral and a poster presentation at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The post indicates that Chief Medical Officer Richard Nkulikiyinka will present data from a first-in-human study of AT7687, described as a first-in-class GIPR antagonist peptide evaluated in healthy participants and individuals living with obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same LinkedIn post notes that Chief Scientific Officer Mads Tang-Christensen will present preclinical data on combining AT7687 with cagrilintide, a dual amylin and calcitonin receptor agonist known for weight-lowering effects. This scientific visibility at a major diabetes conference suggests Antag Therapeutics is progressing both clinical and preclinical assets in obesity and metabolic disease, which may enhance its profile with potential partners and investors focused on incretin-based and combination obesity therapies.
For investors, the first-in-human data readout implied by the presentation could serve as an early indicator of AT7687’s safety, pharmacodynamics, and potential differentiation in a crowded obesity pipeline. If the clinical and preclinical results are favorable, the exposure at the ADA Scientific Sessions could support Antag Therapeutics’ ability to attract strategic collaborations or future funding in the metabolic and obesity treatment space.